Statin-Intolerance Registry

N/AActive Not RecruitingNCT04975594

University of Leipzig1,000 enrolled

Overview

The Statin-Intolerance Registry will characterize the patient population suffering from statin-intolerance which is a frequent but incompletely understood patient condition with important clinical implications for atherosclerotic cardiovascular disease (ASCVD) prevention. Patients will be systematically and prospectively included and followed by the registry.

This non-interventional registry based on routine clinical practice will collect data under real-life conditions. The treatment of patients will not be changed by this study. Data on patient characteristics and the treatment history will be collected via questionnaires at study entree. Yearly follow up visits will re-assess the baseline parameters and document cardiovascular events. The data will be analyzed using descriptive statistics.

Study Type

OBSERVATIONAL

Enrollment

1,000

Conditions

Dyslipidemias

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Patients with dyslipidemia and statin intolerance, defined as: Use of 2 or more statins and intolerance of these drugs in any dose or inability to tolerate dosage increasement beyond a maximum weekly dose of 70 mg atorvastatin, 140 mg Simvastatin, pravastatin, or lovastatin, 35 mg rosuvastatin, 280 mg of Fluvastatin and symptoms improve or disappear when statin is reduced in dosage or discontinued 2. Participants are ≧ 18 years old 3. Written declaration of consent is available 4. The patient is cognitively, linguistically and organizationally capable to meet the study requirements. The possibility of 1 year follow-up is very likely. Exclusion Criteria: 1. Use of any experimental or investigational drugs within 30 days prior to screening. 2. An employee or contractor of the facility conducting the study, or a family member of the principal investigator, co-Investigator, or sponsor.

Locations (1)

Uniklinik Leipzig

Leipzig, Saxony, Germany

Outcomes

Primary Outcomes

Number of treatment adjustments

Time frame: 3 years

Change in LDL cholesterol level

Time frame: 3 years

Secondary Outcomes

Change in quality of life

by EQ-5D

Time frame: 3 years

Development of muscle symptoms over time that initially lead to discontinuation of statin therapy

based on the "Statin-Associated Muscle Symptom Clinical Index" (SAMS-CI)

Time frame: 3 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.